Clinical Trial

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)

MOA: Atebimetinib (IMM-1 104) is a deep cyclic dual inhibitor of MEK1 and MEK2

Key Eligibility:

• Subjects’ initial diagnosis of metastatic pancreatic adenocarcinoma
  must have occurred ≤12 weeks prior to screening
• Subjects has ≥1 lesion measurable by CT/MRI
• Subjects with only localized disease are excluded
• Subjects with squamous, adenosquamous, neuroendocrine, or
  acinar pancreatic carcinoma are excluded
• Subjects that have received prior treatment for disease, except for
  palliative radiation or stent placement, are excluded
• Subjects that have received prior adjuvant therapy for disease are
  excluded, unless ≥6 months have passed since the last dose and
  there are no ongoing treatment-related toxicities.
  • Prior neoadjuvant therapy is permitted